These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23564377)

  • 21. Bevacizumab-induced bowel perforation.
    Sliesoraitis S; Tawfik B
    J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
    Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
    J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
    Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
    Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrovascular events after bevacizumab treatment: an early and severe complication.
    Seet RC; Rabinstein AA; Lindell PE; Uhm JH; Wijdicks EF
    Neurocrit Care; 2011 Dec; 15(3):421-7. PubMed ID: 21547590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
    Budai B; Nagy T; Láng I; Hitre E
    Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia.
    Brinkerhoff BT; Choong NW; Treisman JS; Poetker DM
    Am J Otolaryngol; 2012; 33(3):349-51. PubMed ID: 21917353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia.
    Lazaraki G; Akriviadis E; Pilpilidis I; Parisi I; Tzilves D; Tarpangos A
    Am J Gastroenterol; 2011 Dec; 106(12):2204-6. PubMed ID: 22138950
    [No Abstract]   [Full Text] [Related]  

  • 29. Intricacies of bevacizumab-induced toxicities and their management.
    Gressett SM; Shah SR
    Ann Pharmacother; 2009 Mar; 43(3):490-501. PubMed ID: 19261963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optic atrophy after anti-vascular endothelial growth factor injection in diabetic patients with proliferative diabetic retinopathy.
    Singalavanija A; Hemarat K; Kedkovid N; Tanterdtham J; Namatra C; Trinavarat A; Rodanant N; Thoongsuwan S
    J Med Assoc Thai; 2013 Mar; 96(3):318-23. PubMed ID: 23539935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab treatment for cancer patients with cardiovascular disease: a double edged sword?
    Pereg D; Lishner M
    Eur Heart J; 2008 Oct; 29(19):2325-6. PubMed ID: 18762551
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer.
    Stevenson JP; Langer CJ; Somer RA; Evans TL; Rajagopalan K; Krieger K; Jacobs-Small M; Dyanick N; Milcarek B; Coakley S; Walker S; Eaby-Sandy B; Hageboutros A
    Cancer; 2012 Nov; 118(22):5580-7. PubMed ID: 22544579
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab: more fatal adverse effects.
    Prescrire Int; 2012 Nov; 21(132):266-7. PubMed ID: 23210257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surveillance for potential adverse events associated with the use of intravitreal bevacizumab for retinal and choroidal vascular disease.
    Wong LJ; Desai RU; Jain A; Feliciano D; Moshfeghi DM; Sanislo SR; Blumenkranz MS
    Retina; 2008 Oct; 28(8):1151-8. PubMed ID: 18685542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab 5 mg/kg can be infused safely over 10 minutes.
    Reidy DL; Chung KY; Timoney JP; Park VJ; Hollywood E; Sklarin NT; Muller RJ; Saltz LB
    J Clin Oncol; 2007 Jul; 25(19):2691-5. PubMed ID: 17602073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Surgical management of bevacizumab-associated peritonitis due to perforation].
    Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
    Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab-associated osteonecrosis of the wrist and knee in three pediatric patients with recurrent CNS tumors.
    Fangusaro J; Gururangan S; Jakacki RI; Kaste SC; Goldman S; Pollack IF; Boyett JM; Kun LE
    J Clin Oncol; 2013 Jan; 31(2):e24-7. PubMed ID: 23169504
    [No Abstract]   [Full Text] [Related]  

  • 40. Bevacizumab treatment in hereditary hemorrhagic teleangiectasia.
    Föllner S; Ibe M; Schreiber J
    Eur J Clin Pharmacol; 2012 Dec; 68(12):1685-6. PubMed ID: 22644344
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.